---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-273321"
form_type: "8-K"
ticker: "MNKD"
cik: "0000899460"
company_name: "MANNKIND CORP"
filed_at: "2025-11-10T23:59:59+00:00"
generated_at: "2026-05-16T22:49:49.680787+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis

## Summary
- Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.
- DSMB agreed with decision due to futility; no safety issues identified in any DSMB meetings.
- Company will investigate outcome and focus on advancing MNKD-102 dry powder formulation toward Phase 1.

## SEC filing metadata
- accession: 0001193125-25-273321
- form_type: 8-K
- ticker: MNKD
- cik: 0000899460
- company_name: MANNKIND CORP
- filed_at: 2025-11-10T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/0001193125-25-273321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/899460/000119312525273321/d25083d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-273321
- JSON: https://secwatch.observer/filing/0001193125-25-273321.json
- Plain text: https://secwatch.observer/filing/0001193125-25-273321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.